Jianming Xu

Dr. Jianming Xu


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2011 in Cell Research
Verified
Journal Article
Closed access
PDF file
QQQian Qin
Qian Qin
YXYoung Xu
Young Xu
THTao He
Tao He
CQChunlin Qin
Chunlin Qin
JXJianming Xu
Jianming Xu

17 August 2010 in Cell Research
Verified
Journal Article
Closed access
JFJunjiang Fu
Junjiang Fu
LQLi Qin
Li Qin
THTao He
Tao He
JQJun Qin
Jun Qin
JHJun Hong
Jun Hong
JXJianming Xu
Jianming Xu

1 January 2012 in International Journal of Biological Sciences
Verified
Journal Article
Open access
CWClaire A. Walsh
Claire A. Walsh
LQLi Qin
Li Qin
JTJean Ching-Yi Tien
Jean Ching-Yi Tien
LYLeonie S. Young
Leonie S. Young
JXJianming Xu
Jianming Xu
In 1995, the steroid receptor coactivator-1 (SRC-1) was identified as the first authentic steroid receptor coactivator. Since then, the SRC proteins have remained at the epicenter of coregulator biology, molecular endocrinology and endocrine-related cancer. Cumulative works on SRC-1 have shown that it is primarily a nuclear receptor coregulator and functions to construct highly specific enzymatic protein complexes which can execute efficient and successful transcriptional activation of designated target genes. The versatile nature of SRC-1 enables it to respond to steroid dependent and steroid independent stimulation, allowing it to bind across many families of transcription factors to orchestrate and regulate complex physiological reactions. This review highlights the multiple functions of SRC-1 in the development and maintenance of normal tissue functions as well as its major role in mediating hormone receptor responsiveness. Insights from genetically manipulated mouse models and clinical data suggest SRC-1 is significantly overexpressed in many cancers, in particular, cancers of the reproductive tissues. SRC-1 has been associated with cellular proliferation and tumor growth but its major tumorigenic contributions are promotion and execution of breast cancer metastasis and mediation of resistance to endocrine therapies. The ability of SRC-1 to coordinate multiple signaling pathways makes it an important player in tumor cells' escape of targeted therapy.

9 October 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YXYixiang Xu
Yixiang Xu
DLDong-Kee Lee
Dong-Kee Lee
ZFZhen Feng
Zhen Feng
YXYan Xu
Yan Xu
WBWen Bu
Wen Bu
JXJianming Xu
Jianming Xu
Twist1 is an epithelial–mesenchymal transition (EMT)-inducing transcription factor (TF) that promotes cell migration and invasion. To determine the intrinsic role of Twist1 in EMT and breast cancer initiation, growth, and metastasis, we developed mouse models with an oncogene-induced mammary tumor containing wild-type (WT) Twist1 or tumor cell-specific Twist1 knockout (Twist1TKO). Twist1 knockout showed no effects on tumor initiation and growth. In both models with early-stage tumor cells, Twist1, and mesenchymal markers were not expressed, and lung metastasis was absent. Twist1 expression was detected in ∼6% of the advanced WT tumor cells. Most of these Twist1+ cells coexpressed several other EMT-inducing TFs (Snail, Slug, Zeb2), lost ERα and luminal marker K8, acquired basal cell markers (K5, p63), and exhibited a partial EMT plasticity (E-cadherin+/vimentin+). In advanced Twist1TKO tumor cells, Twist1 knockout largely diminished the expression of the aforementioned EMT-inducing TFs and basal and mesenchymal markers, but maintained the expression of the luminal markers. Circulating tumor cells (CTCs) were commonly detected in mice with advanced WT tumors, but not in mice with advanced Twist1TKO tumors. Nearly all WT CTCs coexpressed Twist1 with other EMT-inducing TFs and both epithelial and mesenchymal markers. Mice with advanced WT tumors developed extensive lung metastasis consisting of luminal tumor cells with silenced Twist1 and mesenchymal marker expression. Mice with advanced Twist1TKO tumors developed very little lung metastasis. Therefore, Twist1 is required for the expression of other EMT-inducing TFs in a small subset of tumor cells. Together, they induce partial EMT, basal-like tumor progression, intravasation, and metastasis.

1 January 2021 in Science
Verified
Journal Article
Closed access
MSManjunatha Shivaraju
Manjunatha Shivaraju
UCUdbhav K. Chitta
Udbhav K. Chitta
RGRobert M. H. Grange
Robert M. H. Grange
IJIsha H. Jain
Isha H. Jain
DCDiane Capen
Diane Capen
JRJayaraj Rajagopal
Jayaraj Rajagopal
Protecting the lung from hypoxic stress: The lung experiences constantly changing oxygen concentrations and must recognize and respond to a low-oxygen environment. Shivaraju et al. reveal that airway stem cells directly sense hypoxia and respond by differentiating into protective neuroendocrine (NE) cells that secrete a peptide that mitigates tissue damage (see the Perspective by Zacharias). This work suggests that the observed NE cell hyperplasia that accompanies lung diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease represents a compensatory physiologic response. More broadly, it raises the possibility that stem cells throughout the body sense hypoxia and differentiate into organ-specific NE cells. Science , this issue p. 52 ; see also p. 32

6 August 2021 in Science
Verified
Journal Article
Closed access
YLYajuan Li
Yajuan Li
ZTZhi Tan
Zhi Tan
YZYaohua Zhang
Yaohua Zhang
XWXin Wang
Xin Wang
QHQingsong Hu
Qingsong Hu
Liuqing YangLiuqing Yang
Liuqing Yang
RNA solution for a genetic problem: Phenylketonuria provides a classic case of the benefit of newborn metabolic screening: It is a single-gene disease that can be detected at birth, and its neurological effects can be prevented by dietary therapy. Unfortunately, this is not always straightforward because the disease-causing mutations in phenylalanine hydroxylase vary between patients and affect the severity of the phenotype, such that some patients’ symptoms do not fully respond to the available interventions. Li et al . identified two long noncoding RNAs, one in mice and one in humans, that interact with phenylalanine hydroxylase and modulate its function (see the Perspective by Ben-Tov Perry and Ulitsky). Administration of modified RNAs mimicking their effects ameliorated the disease phenotype in mouse models of phenylketonuria. —YN